What intravenous (IV) antibiotics are recommended for Pseudomonas aeruginosa coverage?

IV Antibiotics for Pseudomonas Coverage

For empiric Pseudomonas aeruginosa coverage, use an antipseudomonal β-lactam (piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, ceftazidime 2g IV q8h, meropenem 1g IV q8h, or imipenem 500mg IV q6h) as your primary agent. 1

Clinical Decision Algorithm

Step 1: Assess Risk for Multidrug-Resistant (MDR) Pseudomonas

High-risk patients requiring double antipseudomonal coverage include those with:

• Prior IV antibiotic use within 90 days
• Septic shock at time of VAP
• ARDS preceding VAP
• ≥5 days hospitalization before VAP onset
• Acute renal replacement therapy before VAP
• Structural lung disease (bronchiectasis, cystic fibrosis) 1

Step 2: Choose Initial Regimen Based on Risk

For standard-risk patients (no MDR risk factors):

• Single agent from β-lactam options:
  • Piperacillin-tazobactam 4.5g IV q6h, OR
  • Cefepime 2g IV q8h, OR
  • Ceftazidime 2g IV q8h, OR
  • Meropenem 1g IV q8h, OR
  • Imipenem 500mg IV q6h 1

For high-risk patients (MDR risk factors present):

• Combine one β-lactam (above) PLUS one of the following from a different class:
  • Ciprofloxacin 400mg IV q8h, OR
  • Amikacin 15-20mg/kg IV q24h, OR
  • Gentamicin 5-7mg/kg IV q24h, OR
  • Tobramycin 5-7mg/kg IV q24h 1

Critical caveat: Avoid combining two β-lactams. Aztreonam 2g IV q8h can be used as an exception when combined with another β-lactam because it has different bacterial cell wall targets 1

Step 3: Consider Extended Infusions

Extended or continuous infusions of β-lactams are appropriate for pharmacokinetic/pharmacodynamic optimization, particularly in critically ill patients 1

Step 4: Adjust for Specific Clinical Scenarios

For difficult-to-treat resistant (DTR) Pseudomonas:

• Preferred newer agents (when susceptible):
  • Ceftolozane-tazobactam (preferred for pneumonia)
  • Ceftazidime-avibactam (equally effective for non-pulmonary infections)
  • Imipenem-relebactam
  • Cefiderocol (especially for metallo-β-lactamase producers) 2, 3

For carbapenem-resistant Pseudomonas (CRPA):

• Ceftolozane-tazobactam is suggested for severe infections if active in vitro 2
• When treating with polymyxins, aminoglycosides, or fosfomycin, use two in vitro active drugs for severe infections 2

Important Pitfalls to Avoid

Aminoglycoside considerations: Meta-analysis shows aminoglycoside regimens have lower clinical response rates with no mortality differences, making them less preferred as monotherapy 1

Polymyxin use: Reserve colistin (5mg/kg IV loading, then 2.5mg × [1.5 × CrCl + 30] IV q12h) and polymyxin B (2.5-3.0mg/kg/d divided q12h) for settings with high MDR prevalence and local expertise 1

Dose adjustments required: Drug levels and dose/interval adjustments are mandatory for aminoglycosides, glycopeptides, and polymyxins 1

Imipenem seizure risk: Lower doses in patients <70kg to prevent seizures 1

Local antibiogram essential: Empiric regimens must be informed by your institution's local distribution of pathogens and antimicrobial susceptibilities 1

Combination Therapy Controversy

Current evidence does NOT support routine combination therapy for DTR Pseudomonas infections despite in vitro synergy and animal model data, as clinical evidence is lacking 3. However, combination therapy is suggested for severe infections when only older agents (polymyxins, aminoglycosides, tigecycline, fosfomycin) are active in vitro 2